Comprehensive Cost of Illness of Three Major Diseases in Japan

Matsumoto, Kunichika; Hanaoka, S; Wu, Yufei; Hasegawa, Tomonori

doi:10.1016/j.jstrokecerebrovasdis.2017.06.022

Cited by 26 publications

(38 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used the COI method to examine the economic burden of non‐alcoholic liver cirrhosis. The calculation method used in this study was the same as that of our previous study . First, we calculated the COIs for 1996, 1999, 2002, 2005, 2008, 2011, and 2014.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cost of illness of non‐alcoholic liver cirrhosis in Japan: A time trend analysis and future projections

Kitazawa

Matsumoto

Fujita

et al. 2017

Hepatology Research

Self Cite

View full text Add to dashboard Cite

The results of this study suggest that the COI of non-alcoholic liver cirrhosis in Japan has steadily decreased and will continue to decrease. Treatment of patients with hepatitis C virus infection with newly introduced technologies has high therapeutic effectiveness, which will affect the future prevalence of non-alcoholic liver cirrhosis. When interpreting the results of long-term estimation, it should be noted that the results of this study were based on present conditions.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The calculation method used in this study was the same as that of our previous study. 16 First, we calculated the COIs for 1996, 1999, 2002, 2005, 2008, 2011, and 2014. We then predicted future COIs 17-20 based on those results.…”

Section: Methodsmentioning

confidence: 99%

Cost of illness of non‐alcoholic liver cirrhosis in Japan: A time trend analysis and future projections

Kitazawa

Matsumoto

Fujita

et al. 2017

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Data on the national economic burden of CVD in the other mega-countries were collected from a included series of studies and reports [51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70]. Beginning with countries of a low and middle HDI, data of projected economic losses due to CVD in India between 2012 and 2030 were identified in a study Evidence of CVD economic impact for mega-countries with a very high HDI were identified in seven sources.…”

Section: Literature Searchmentioning

confidence: 99%

Attributable burden and expenditure of cardiovascular diseases and associated risk factors in Mexico and other selected mega-countries

Mendoza-Herrera

Pedroza-Tobías

Hernández-Alcaraz

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Cardiovascular diseases (CVD) represent a health and economic threat globally. This paper aims to describe this problem in Mexico and other selected mega-countries through a review of published literature and the exploration of secondary datasets. Method Mega-countries with low (Nigeria), middle (India), high (China/Brazil/Mexico), and very high (the U.S./Japan) human development index (HDI) were included. The review was divided into two topics: prevalence of dyslipidemia and CVD economic impact. Search, screening, and filtering processes were conducted in electronic databases using MeSH terms by one trained researcher. Inclusion and exclusion criteria were considered for eligibility. Methods and results were reported according to the PRISMA statement. Information from datasets on epidemiologic CVD indicators was also extracted. Results Thirty-two studies were eligible. Heterogeneity in economic data and limited nationwide information on dyslipidemias prevalence in some countries were found. Hypertriglyceridemia and hypercholesterolemia were higher in Mexico compared to other countries. Dietary risk factors have a higher contribution on cardiovascular mortality in developing countries: e.g. 8.1-13.8% Mexico, 11.3-13.0% India vs. 0.078-8.9% Japan, 6.5-10.7% the U.S. Probability of dying prematurely from CVD in 2016 was higher in lower HDI countries: 23.3-22.5% (low-middle), 17.0-15.7% (high), and 14.6-8.4% (very high). From 1990-2016, a greater decrease in cardiovascular mortality in developed countries was registered (-56.8% Japan/-11.1% India). In 2015, an expenditure of USD-PPP $11.2 billion due to hypertension, myocardial infarction, atrial fibrillation, and heart failure was reported in Mexico (4% from public health expenditure). CVD ranked first in health care expenditures in almost all these nations and this economic burden is expected to remain significant by 2030, especially in the most populated or developed countries. Conclusions The higher burden of CVD and its significant economic impact, coupled with poor clinical practice and epidemiological surveillance, represents a greater challenge for Mexico and other developing mega-countries. Thus, governments and academia should secure resources to assure an optimal monitoring of cardiovascular risk factors. Educational models and medical practice must be improved to optimize the diagnosis of CVD and the prescription and adherence of their pharmacological and lifestyle treatments. Long-term benefits are expected from strengthening strategies to modify the food system.

show abstract

“…Calculation and comparison of the social burden of diseases is also necessary in prioritizing for assignment. In Japan , development and its applicability of cost‐of‐illness (COI) study have been introduced, and a comparison of the social burden of nine major cancers was made . However, whereas a wide range of knowledge has been obtained regarding the clinical features of both cervical and endometrial cancers, no studies have compared them from the standpoint of economic burden.…”

Section: Introductionmentioning

confidence: 99%

“…In Japan, development and its applicability of cost-of-illness (COI) study have been introduced, 1 and a comparison of the social burden of nine major cancers was made. 2 However, whereas a wide range of knowledge has been obtained regarding the clinical features of both cervical and endometrial cancers, no studies have compared them from the standpoint of economic burden. Data regarding economic burden are important for informing health policy decision-making on this topic, including policies regarding routine prophylactic vaccination against cervical cancer and expansion of outpatient services for the treatment of endometrial cancer.…”

Section: Introductionmentioning

confidence: 99%

Informing health policy in Japan: A mixed‐model estimation to compare the cost of illness of cervical cancer and endometrial cancer

Hayata

Seto

Kitazawa

et al. 2015

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

Aim: The objective of this study was to inform Japanese health policy by comparing cervical cancer and endometrial cancer from the standpoint of economic burden and examining factors affecting future changes in economic burden. Methods: Using government-based nationwide statistical data, we used the cost-of-illness (COI) method to estimate the COI from 1996 to 2011 and predicted future estimates for 2014, 2017, and 2020. Results: In 2011, the COI of cervical cancer was estimated at 159.9 billion yen and that of endometrial cancer was estimated at 99.5 billion yen. Assuming the current trends in health-related indicators, the COI of cervical cancer is predicted to temporarily decrease in 2014 and then remain constant. Meanwhile, the COI of endometrial cancer is predicted to temporarily decrease in 2014 before returning to an upward trend. Conclusion: The COI of both cervical cancer and endometrial cancer is estimated to remain constant or increase in the future. The average age of death from cervical cancer is predicted to remain relatively young and the high human capital value of patients who die in their sixties is the most likely explanation for the lack of decrease in future COI. As women's participation in society continues to increase, the future COI may also increase. Regarding endometrial cancer, the increase in direct costs, particularly hospitalization costs, is a likely factor resulting in the increase in the COI. This is because women are surviving longer, and thus receiving care for longer durations, because of advancements in medical care.

show abstract

Comprehensive Cost of Illness of Three Major Diseases in Japan

Cited by 26 publications

References 23 publications

Cost of illness of non‐alcoholic liver cirrhosis in Japan: A time trend analysis and future projections

Cost of illness of non‐alcoholic liver cirrhosis in Japan: A time trend analysis and future projections

Attributable burden and expenditure of cardiovascular diseases and associated risk factors in Mexico and other selected mega-countries

Informing health policy in Japan: A mixed‐model estimation to compare the cost of illness of cervical cancer and endometrial cancer

Contact Info

Product

Resources

About